Oklahoma AG Drummond Warns of Gaps in Drug Supply Chain, Cites Chinese Supplier in Letter to Rubio

Oklahoma Attorney General Gentner Drummond has joined 19 other state attorneys general in a letter to Secretary of State Marco Rubio, warning that gaps in federal oversight are allowing Chinese suppliers to move potentially dangerous pharmaceutical ingredients into the U.S. market. The letter focuses on ingredients used in compounded GLP-1 drugs such as semaglutide, tirzepatide and retatrutide, the same class of medications many Oklahomans use for weight loss and diabetes.

The attorneys general singled out Harbin Jixianglong Biotech Co., which they say purchased semaglutide from an unregistered facility, then repackaged and relabeled it for distribution to the United States. The coalition is pressing for stricter oversight of the FDA’s Green List program, or failing that, a block on dangerous ingredients entering the country. They also flagged a Chinese business with ties to fentanyl manufacturers and urged the National Security Council to address the supply chain concerns.

For Lawton and Fort Sill families, the stakes are practical. Compounded medications can be a lifeline, but the ingredients behind them are only as trustworthy as the inspections that verify them. If you take a compounded prescription, your pharmacist can tell you where the ingredients were sourced, and that is a fair question to ask.

Do you check where your medication comes from, or do you trust the label? Let us know in the comments.